SB 987 — Maryland
Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; providing for the distribution of revenue attributable to the addition modification; etc.
Latest action: Hearing 3/11 at 1:00 p.m. · Mar 5, 2026
Synopsis written by the legislature's own staff, as published on the official bill page. Status label is derived from the recorded actions. The full text below is the record.
Committees: Budget and Taxation (Senate)
Updated Mar 17, 2026
Timeline
First Reading Senate Rules
Feb 15, 2026 · Senate
Rereferred to Budget and Taxation
Mar 4, 2026 · Senate
Hearing 3/11 at 1:00 p.m.
Mar 5, 2026 · Senate
Sponsored by Karen Young
No recorded floor votes yet.
How we know this
Every line above comes from the Maryland General Assembly record via Open States. The motion text is shown as recorded, so a procedural vote (to amend, refer or reconsider) is not read as a vote on the bill itself. The source does not say which text version each vote was on; every version is linked below.
Official records. Maryland legislators, bills and roll-call votes from the Maryland General Assembly, imported through Open States on Oct 29, 2026. Accuracy review against the official site is still under way. Campaign-finance records for Maryland are not imported yet.